嵌合抗原受体T细胞疗法在免疫介导神经系统疾病中的作用
本文综述了CAR-T疗法在免疫介导神经系统疾病中的应用现状与未来方向。尽管高效疾病修饰治疗已应用,部分患者仍疾病活动并进展;自体造血干细胞移植有效但毒性大。CAR-T在B细胞驱动的免疫介导疾病(如系统性红斑狼疮、视神经脊髓炎谱系疾病、重症肌无力)早期试验中显示显著临床反应且不良事件少;基于共同病理生理,CAR-T可能成为多发性硬化、慢性炎性多神经根病、自身免疫性脑炎、僵人综合征等的有效选择,避免长期免疫抑制剂,并可能比自体造血干细胞移植更具选择性、疗效更高且不良事件更少。
要点
- CAR-T在系统性红斑狼疮、视神经脊髓炎谱系疾病、重症肌无力早期试验中显示显著临床反应且不良事件少。
- CAR-T可能成为多发性硬化、慢性炎性多神经根病、自身免疫性脑炎、僵人综合征的有效选择。
- CAR-T可能比自体造血干细胞移植更具选择性、疗效更高且不良事件更少。
核心结论
- 基于共同病理生理,CAR-T疗法在其他免疫介导神经系统疾病中可能是一种有效选择,避免长期免疫抑制剂使用。
- CAR-T可能被证明是比自体造血干细胞移植更具选择性的免疫消融方法,可能疗效更高且不良事件更少。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 尽管使用高效疾病修饰治疗,部分免疫介导神经系统疾病患者仍疾病活动并临床进展,导致残疾累积、社会心理健康恶化及高经济负担。
- 自体造血干细胞移植是有效治疗方式,但为基于强化化疗的治疗,伴一系列短期和长期副作用。
- CAR-T疗法革新了B细胞及其他血液系统恶性肿瘤的治疗,使难治性疾病获得长期缓解。
- CAR-T治疗毒性(尤其细胞因子释放综合征和免疫效应细胞相关神经毒性综合征)及生产复杂性要求治疗中心高度专业化。
- CAR-T在系统性红斑狼疮、视神经脊髓炎谱系疾病和重症肌无力等免疫介导B细胞驱动疾病的早期试验中显示显著临床反应且不良事件少。
关键数值与推荐
- 原文未报告具体推荐条款或数值标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- CAR-T治疗毒性包括细胞因子释放综合征和免疫效应细胞相关神经毒性综合征,且生产复杂性要求治疗中心高度专业化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the use of 'high efficacy' disease-modifying therapies, disease activity and clinical progression of different immune-mediated neurological diseases continue for some patients, resulting in accumulating disability, deteriorating social and mental health, and high economic cost to patients and society. Although autologous hematopoietic stem cell transplant is an effective treatment modality, it is an intensive chemotherapy-based therapy with a range of short- and long-term side-effects. Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the treatment of B-cell and other hematological malignancies, conferring long-term remission for otherwise refractory diseases. However, the toxicity of this treatment, particularly cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and the complexity of production necessitate the need for a high level of specialization at treating centers. Early-phase trials of CAR-T therapies in immune-mediated B cell driven conditions, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder and myasthenia gravis, have shown dramatic clinical response with few adverse events. Based on the common physiopathology, CAR-T therapy in other immune-mediated neurological disease, including multiple sclerosis, chronic inflammatory polyradiculopathy, autoimmune encephalitis, and stiff person syndrome, might be an effective option for patients, avoiding the need for long-term immunosuppressant medications. It may prove to be a more selective immunoablative approach than autologous hematopoietic stem cell transplant, with potentially increased efficacy and lower adverse events. In this review, we present the state of the art and future directions of the use of CAR-T in such conditions. ANN NEUROL 2024;96:441-452.
引用
- Brittain G, Roldan E, Alexander T, et al. The Role of Chimeric Antigen Receptor T-Cell Therapy in Immune-Mediated Neurological Diseases. Ann Neurol. 2024. PMID: 39015040. doi:10.1002/ana.27029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。